

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

Anti-CD44 antibody

RRID:AB_2847859

Type: Antibody

Proper Citation

Abcam Cat# ab157107, RRID:AB_2847859

Antibody Information

URL: http://antibodyregistry.org/AB_2847859

Proper Citation: Abcam Cat# ab157107, RRID:AB_2847859

Target Antigen: CD44

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: ICC/IF, WB, IP, Flow Cyt, IHC-P
Validation: data for WB is available from YCharOS.
<https://doi.org/10.5281/zenodo.4730966>

Antibody Name: Anti-CD44 antibody

Description: This polyclonal targets CD44

Target Organism: rat, mouse, human

Antibody ID: AB_2847859

Vendor: Abcam

Catalog Number: ab157107

Record Creation Time: 20250820T010421+0000

Record Last Update: 20250820T095721+0000

Ratings and Alerts

- Head to head comparison of available commercial antibodies against CD44 antigen using a knockout cell line by immunoblot (Western blot), immunoprecipitation and immunofluorescence. - YCHarOS <https://doi.org/10.5281/zenodo.4730966>

No alerts have been found for Anti-CD44 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Salmazo MIBF, et al. (2025) Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle invasive bladder cancer. Tissue & cell, 93, 102783.

Lorenzo-Martín LF, et al. (2025) Bioengineering mini-colons for ex vivo colorectal cancer research. Nature protocols.

Zhang L, et al. (2025) Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. Cancer research, 85(1), 134.

Martínez Santamaría JC, et al. (2025) Fibrinogen triggers perivascular fibroblast activation in a mouse model of cortical ischemic stroke. iScience, 28(11), 113834.

Rothe R, et al. (2024) Programmable Release of Chemotherapeutics from Ferrocene-Based Injectable Hydrogels Slows Melanoma Growth. Advanced healthcare materials, 13(27), e2400265.

Wang X, et al. (2024) LncRNA IRAIN overcomes imatinib resistance in chronic myeloid leukemia via NF- κ B/CD44 pathway inhibition. iScience, 27(6), 109851.

Park SS, et al. (2024) Cellular senescence is associated with the spatial evolution toward a higher metastatic phenotype in colorectal cancer. Cell reports, 43(3), 113912.

Diep CH, et al. (2024) Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer. Endocrinology, 165(9).

Pruvost M, et al. (2023) The stability of the myelinating oligodendrocyte transcriptome is regulated by the nuclear lamina. Cell reports, 42(8), 112848.

Takasugi M, et al. (2023) CD44 correlates with longevity and enhances basal ATF6 activity and ER stress resistance. Cell reports, 42(9), 113130.

Wu Z, et al. (2023) Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer. EMBO reports, 24(4), e56524.

Ganguly K, et al. (2022) Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. *Gastroenterology*, 162(7), 2032.

Decano JL, et al. (2022) A disease-driver population within interstitial cells of human calcific aortic valves identified via single-cell and proteomic profiling. *Cell reports*, 39(2), 110685.

Kumar R, et al. (2022) Gender-based effect of absence of gut microbiota on the protective efficacy of *Bifidobacterium longum*-fermented rice bran diet against inflammation-associated colon tumorigenesis. *Molecular carcinogenesis*, 61(10), 941.

Laohavisudhi F, et al. (2022) Evaluation of CD44s, CD44v6, CXCR2, CXCL1, and IL-1 β in Benign and Malignant Tumors of Salivary Glands. *Diagnostics (Basel, Switzerland)*, 12(5).

Venkataramani V, et al. (2022) Glioblastoma hijacks neuronal mechanisms for brain invasion. *Cell*, 185(16), 2899.

Wareham LK, et al. (2021) Interleukin-6 promotes microtubule stability in axons via Stat3 protein-protein interactions. *iScience*, 24(10), 103141.

Rothe R, et al. (2021) A modular, injectable, non-covalently assembled hydrogel system features widescale tunable degradability for controlled release and tissue integration. *Biomaterials*, 269, 120637.